Why the study?
Does PAI-1 deficiency prevent hypertension and vascular fibrosis in response to long-term NOS inhibition in male mice?
Does PAI-1 deficiency prevent hypertension and vascular fibrosis in response to long-term NOS inhibition in male mice?
PAI-1 deficiency protects against structural vascular changes and hypertension induced by long-term NOS inhibition in mice, suggesting vascular PAI-1 as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
PAI-1 deficiency attenuates hypertension in this model; hypothesis-generating for therapeutic targeting and requires human validation before any clinical consideration.
BACKGROUND: Long-term inhibition of nitric oxide synthase (NOS) is known to induce hypertension and perivascular fibrosis. Recent evidence also suggests that long-term NOS inhibition induces expression of plasminogen activator inhibitor-1 (PAI-1) in vascular tissues and that PAI-1 may contribute to the development of fibrosis after chemical or ionizing injury. On the basis of these observations, we hypothesized that PAI-1 may influence the vascular response to long-term NOS inhibition by N(omega)-nitro-L-arginine methyl ester (L-NAME). METHODS AND RESULTS: We compared the temporal changes in systolic blood pressure and coronary perivascular fibrosis in PAI-1-deficient (PAI-1(-/-)) and wild-type (WT) male mice (N=6 per group). At baseline, there were no significant differences in blood pressure between groups. After initiation of L-NAME, systolic blood pressure increased in both groups at 2 weeks. Over an 8-week study period, systolic blood pressure increased to 141+/-3 mm Hg in WT animals versus 112+/-4 mm Hg in PAI-1(-/-) mice (P<0.0001). The extent of coronary perivascular fibrosis increased significantly in L-NAME-treated WT mice (P<0.01 versus PAI-1(-/-) mice). Cardiac type I collagen mRNA expression was greater in control (P<0.01) and L-NAME-treated PAI-1(-/-) (P<0.05) groups than in control WT mice, indicating that PAI-1 deficiency prevents the increase of collagen deposition by promoting matrix degradation. CONCLUSIONS: These findings suggest that PAI-1 deficiency alone is sufficient to protect against the structural vascular changes that accompany hypertension in the setting of long-term NOS inhibition. Direct inhibition of vascular PAI-1 activity may provide a new therapeutic strategy for the prevention of arteriosclerotic cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Kaikita et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: